This past week, NPR reported on a new variation on repetitive transcranial magnetic stimulation (rTMS) called “Stanford neuromodulation therapy.” In this advancement to rTMS, imaging technology is added to the treatment and the dose of rTMS is increased. The results are a more effective treatment that works more than eight times faster than current rTMS.
According to the NPR report, “Stanford’s neuromodulation therapy could be widely available by the end of this year — that’s when scientists are hoping FDA clearance comes through.”
This is very exciting news for those of us who have tried everything and are still in the market for an effective treatment that is lasting, affordable and that works without side effects that are disabling or otherwise compromising.
“This study shows this new personalized treatment is effective and works quickly, evidenced by 79% of people entering remission after only five days of treatment,” said Brandon Bentzley, M.D., Ph.D., co-founder and CSO of Magnus Medical, and co-first author of the study. “This is revolutionary for people suffering from acute intractable major depression, and it addresses a major unmet need in psychiatry, especially in the emergency hospital setting, where effective treatment can be significantly limited.”
xoxoxo, d (and bella)
American Journal of Psychiatry Abstract on Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
NPR Health News report from February 6, 2022 An experimental depression treatment uses electric currents to bring relief
Businesswire article on Magnus Medical Launch after FDA Breakthrough Device Designation for Treatment
NPR Health News report on Esketamine
Other Posts on Depression: